Q4 2025 CareDx Inc Earnings Call Transcript
Key Points
- CareDx Inc (CDNA) reported a strong financial performance for Q4 2025 with a 25% year-over-year revenue growth, reaching $108 million.
- The company launched new products, including AllasSure Heart for Pediatrics and AllasSure Plus, enhancing its offerings in heart and kidney transplantation.
- CareDx Inc (CDNA) maintained a robust non-GAAP gross margin of 69% and generated a positive adjusted EBITDA of $7 million in the quarter.
- The company ended the quarter with approximately $200 million in cash equivalents and marketable securities, and no debt, providing significant financial flexibility.
- CareDx Inc (CDNA) achieved important regulatory milestones, including IVDR certification for ALTX and Q-Type in Europe, positioning the lab products business for sustained growth.
- The company anticipates a potential $15 million negative revenue impact in 2026 due to the draft local coverage determination for solid organ transplant.
- CareDx Inc (CDNA) reported a decrease in adjusted EBITDA by 34% compared to the previous year, despite the overall revenue growth.
- The company faces challenges in predicting the long-term impact of Epic Aura integrations on volume growth, with uncertainty around the lift it will provide.
- There is a potential risk associated with the implementation of the LCD policy, which could negatively impact revenue and adjusted EBITDA.
- The company is investing significantly in enterprise systems, including Epic Enterprise, which could impact short-term profitability.
Hello everyone Thank you for joining us and welcome to the CARE DX Q4 2025 financial results earnings call.
After today's prepared remarks, we will host a question-and-answer session.
If you would like to ask a question, please press 1 on your telephone keypad.
To withdraw your question, press one again.
I will now hand the call over to Caroline Corner, Investor relations. Please go ahead.
Thank you, operator. Good afternoon.
Thank you for joining us today. Earlier today, CARDX released financial results for the 4th quarter and full year 2025 ending December 31, 2025. These results are currently available on the company's website at www.ARDX.com. Joining me on today's call are John Hannah, President and Chief Executive Officer, Keith Kennedy, Chief Operating Officer, and Nathan Smith, Chief Financial Officer.
Before we get started, I would like to remind everyone that management will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
